September 30, 2024 — Fresenius Kabi, an operating company of Fresenius, specializing in biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs for critical and chronic conditions, and Formycon AG, a leading…Original Article
FDA Approves Otulfi (ustekinumab-aauz), a Biosimilar to Stelara
